Quetiapine/Protease Inhibitors Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Your other medicine may slow down how quickly your liver processes quetiapine.
What might happen:
The amount of quetiapine in your blood may increase and cause more side effects, including irregular heartbeat, which can be life-threatening.
What you should do about this interaction:
Make sure your healthcare professional (e.g. doctor or pharmacist) know that you are taking these medicines together, especially if the medicines were prescribed by different doctors. Your doctor may want to lower the dose of your quetiapine while you are taking your other medicine. Let your doctor know if you notice an increase in side effects from your medicine, especially excessive drowsiness, rapid pulse, weakness, fatigue, dizziness, or uncontrolled muscle movements.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and- drug-interactions-table-substrates-inhibitors-and-inducers. Updated 11/14/2017.
- 2.Seroquel (quetiapine) US prescribing information. AstraZeneca Pharmaceuticals LP September, 2020.
- 3.Seroquel (quetiapine) Canada prescribing information. AstraZeneca Canada Inc. May 15,2013.
- 4.Seroquel (quetiapine) UK summary of product characteristics. Luye Pharma Limited June, 2020.
- 5.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.
- 6.Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol 2006 Jan;61(1):58-69.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.